Labo Euromedis (FRA:61R) ROCE %: 4.33% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:61R Labo Euromedis FRA:61R
61 GF Score
Price €4.76
GF Value €4.37
! 6 Warning Signs
View Full Analysis

What is Labo Euromedis ROCE %?

Labo Euromedis FRA:61R +0.42% 61 ROCE % is 4.33% as of Dec. 2025. GuruFocus rates FRA:61R with a GF Score™ of 61/100 and a GF Value™ of €4.37. The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Labo Euromedis's annualized ROCE % for the quarter that ended in Dec. 2025 was 4.33%.

Labo Euromedis  (FRA:61R) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Labo Euromedis ROCE % Related Terms

Labo Euromedis ROCE % Historical Data

* Premium members only.

The historical data trend for Labo Euromedis's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Labo Euromedis ROCE % Chart

Labo Euromedis Annual Data
Trend Jul15 Jul16 Jul17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.84 -10.30 50.22 2.86 3.21

Labo Euromedis Semi-Annual Data
Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.99 -2.22 8.54 1.82 4.33
FRA:61R
61GF Score
Labo Euromedis FRA:61R
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Labo Euromedis ROCE % Calculation

Labo Euromedis's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=0.904/( ( (38.788 - 10.661) + (39.493 - 11.369) )/ 2 )
=0.904/( (28.127+28.124)/ 2 )
=0.904/28.1255
=3.21 %

Labo Euromedis's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=1.274/( ( (39.777 - 9.087) + (39.493 - 11.369) )/ 2 )
=1.274/( ( 30.69 + 28.124 )/ 2 )
=1.274/29.407
=4.33 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 4.33% mean?
Labo Euromedis (FRA:61R) has a ROCE % of 4.33% as of Dec. 2025.
Is Labo Euromedis' ROCE % too high?
Labo Euromedis' current ROCE % is 4.33%. The Medical Distribution industry median ROCE % is 9.09. Labo Euromedis' value of 4.33% is 52.4% below this industry median. Overall, Labo Euromedis has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' ROCE % compare to MCK and CAH?
Labo Euromedis' ROCE % of 4.33% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.09. Labo Euromedis' value of 4.33% is 52.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 9.09, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current ROCE % of 4.33% is 52.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current ROCE % is 4.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current ROCE % of 4.33%. The stock's GF Value™ is €4.37, compared to a current price of €4.76 — trading 8.9% above its estimated fair value. The current ROCE % is 4.33% and 52.4% below the Medical Distribution industry median of 9.09. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current ROCE % is 4.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Labo Euromedis (FRA:61R) Overvalued in 2026?

Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued. The current stock price of €4.76 is trading 8.9% above its estimated GF Value™ of €4.37.

Key valuation signals for FRA:61R:

  • ROCE %: 4.33%
  • GF Value™: €4.37 vs. price of €4.76 (8.9% above fair value)
  • GF Score™: 61/100 with 6 warning signs
  • Industry Position: 52.4% below the Medical Distribution median

No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Labo Euromedis Business Description

Address ZI de la Tuilerie, Neuilly-sous-Clermont, FRA, 60290
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score

Get the complete analysis for FRA:61R

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.76
Price
€4.37
GF Value